Skip to main content
. 2010 Nov;51(11):3281–3288. doi: 10.1194/jlr.M010330

TABLE 1.

Anthropometric and biochemical parameters of controls and patients with CAD

Control (n = 1123) CAD (n = 807)
Male/Female, (%) 78.4/21.6 81.5/18.5
Age (yr) 56.1 ± 0.23 56.9 ± 0.34
BMI (kg/m2) 24.1 ± 0.07 25.1 ± 0.10
Blood pressure (mm Hg)
Systolic 124.1 ± 0.46 127.2 ± 0.60
Diastolic 78.4 ± 0.32 77.3 ± 0.36
Fasting glucose (mg/dl)a 86.6 ± 0.24 88.8 ± 0.44*
Triglycerides (mg/dl)a 128.9 ± 2.22 147.3 ± 2.80***
ApoA5 (ng/ml)a 225.1 ± 3.55 197.4 ± 5.02***
Total-cholesterol (mg/dl) 195.5 ± 0.99 166.2 ± 1.38***
LDL-cholesterol (mg/dl) 117.9 ± 0.91 90.7 ± 1.25***
HDL-cholesterol (mg/dl)a 51.7 ± 0.42 45.5 ± 0.39***
LDL particle size (nm) 23.76 ± 0.02 23.47 ± 0.03***
TNF-α (pg/ml)a 5.38 ± 0.10 5.65 ± 0.43
hs-CRP (mg/dl)a 1.14 ± 0.06 2.08 ± 0.15***
Malondialdehyde (nmol/ml)a 9.18 ± 0.09 10.5 ± 0.17***
8-epi-PGF (pg/mg creatinine)a 1296.4 ± 18.2 1417.5 ± 27.0***
Ox-LDL (μ/l)a 63.5 ± 0.75 59.5 ± 0.89***
FA composition (%) in serum PL
Total polyunsaturated ω-6 FA 20.6 ± 0.19 20.6 ± 0.20
18:2(ω-6) 12.9 ± 0.13 12.1 ± 0.13***
18:3(ω-6)a 0.27 ± 0.01 0.24 ± 0.01
20:2(ω-6)a 0.63 ± 0.05 0.36 ± 0.01***
20:3(ω-6) 1.61 ± 0.03 1.86 ± 0.03***
20:4(ω-6) 4.84 ± 0.07 5.72 ± 0.10***
Total polyunsaturated ω-3 FA 5.39 ± 0.09 5.51 ± 0.12
18:3(ω-3)a 0.16 ± 0.00 0.17 ± 0.01
20:3(ω-3)a 0.09 ± 0.01 0.08 ± 0.00*
20:5(ω-3)a 1.28 ± 0.03 1.44 ± 0.05
22:5(ω-3)a 0.60 ± 0.01 0.60 ± 0.01
22:6(ω-3)a 3.25 ± 0.06 3.21 ± 0.07
20:4(ω-6)/20:3(ω-6) 3.17 ± 0.04 3.21 ± 0.06*
AA/LA 0.38 ± 0.01 0.48 ± 0.01
APOA5 -1131T>C, n(%)
TT 566 (50.4) 363 (45.0)
TC 455 (40.5) 367 (45.5)
CC 102 (9.1) 77 (9.5)
FEN1 10154 G>T, n(%)
GG 516 (45.9) 399 (49.4)
GT 494 (44.0) 330 (40.9)
TT 113 (10.1) 78 (9.7)

Mean ± SE. P-values were tested with a paired t-test. *P < 0.05, **P < 0.01, ***P < 0.001; adjusted for sex, age, BMI, cigarette smoking, alcohol consumption, and systolic and diastolic BP.

a

Logarithmic transformation.